Based on the data obtained in this article and other publications linking mTORi to improved response, we believe that non-responders may benefit from switching therapy to include an mTOR inhibitor (such as Everolimus) to increase response to vaccination, provided it is not contraindicated (proteinuria, allergy, or serious adverse effects on previous mTORi treatment). This evidence concerns the gene MTOR and Allergy.